



Memorandum

Date: December 5, 2016
To: All Calgary Sunrise Clinical Manager (SCM) Users
From: Dr. Leland Baskin, Acting Clinical Section Chief, Transfusion Medicine
Re: **Change to SCM Transfusion Medicine Order Sheets**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Messages:

- Transfusion Medicine order sets will now **require an order for a transfusion rate** for all blood components (red blood cells, plasma, platelets, cryoprecipitate).

Importance/Impact:

- The order for infusion of blood component and products is parallel to that of any other intravenous fluid or medication, and without the prescription of an infusion rate, patient safety is at risk of compromise.
- Changes to the SCM Transfusion Medicine order sets will include:
 - Mandatory selection of a transfusion rate in an "Infuse Over" drop-down menu, indicated by *
 - Removal of the "*as per relevant policy/procedure*" rate option
 - Inclusion of suggested red blood cell transfusion rates
 - Quick-links to AHS Transfusion Medicine component information resources under PCIS in SCM

Background:

- According to the *AHS Policy for Transfusion of Blood Components and Products*, a transfusion rate must be included by an authorized prescriber of blood component and product transition. The Provincial policy is found at: <http://www.albertahealthservices.ca/lab/Page10380.aspx>.

Action Required:

- The order for a transfusion rate for all blood components must include a defined product volume over a defined period of time, up to a maximum of 4 hours from the time of issue. Approved AHS blood component information/monograph documents may be found at: <http://www.albertahealthservices.ca/lab/Page3319.aspx>.
- Obtain informed consent by an authorized prescriber prior to transfusion of any blood components or products. Information on informed consent to treatment/procedure may be found at: <http://insite.albertahealthservices.ca/2270.asp>.
- A FAQ sheet dedicated to patient consent for blood may be found at: <http://www.albertahealthservices.ca/lab/Page4242.aspx>.

Inquiries and feedback may be directed to:

Tara-Lyn Redfern, Calgary Transfusion Safety Office, 403-944-1900, Tara-Lyn.Redfern@albertahealthservices.ca

This memorandum has been reviewed and approved by::

Leland Baskin, MD, MS, FCAP, FACB, VP Medical Operations, Deputy Medical Directory, Calgary Laboratory Services